目的分析不稳定型心绞痛患者应用小剂量尿激酶治疗前后内皮源性血管活性物质的变化,探讨小剂量尿激酶治疗心绞痛的机理.方法选择104例心电图负荷试验阳性、动态心电图出现缺血性改变的不稳定型心绞痛患者,于小剂量尿激酶治疗前后分别测定内皮素-1、组织型纤溶酶原激活物及其抑制剂的变化.结果小剂量尿激酶治疗后与治疗前相比较,组织型纤溶酶原激活物升高,内皮素-1及组织型纤溶酶原激活物抑制剂下降,其变化均具有显著性.结论小剂量尿激酶可明显调节不稳定型心绞痛患者常测定的内皮源性血管活性物质如内皮素-1、组织型纤溶酶原激活物及其抑制剂的活性,从而有效的治疗冠心病.%[Objective] To analyze the changes of vasoactive substances originated endothelium in patients with unstable angina pectoris treated by low dose of urokinase and explore mechanisms of the drug to treat the unstable angina pectoris. [Methods] 104 patients of unstable angina pectoris were studied. Their ECG stress tests were abnormal and there were ischemic changes in Holter. Before and after urokinase treatments, endothelin-1, plasma tissue plasminogen activator and its inhibitor-lwere determined. [ Results] Compared with pretreatments, after treatments,the activities of tissue plasminogen activator increased, endothelin-1 and the inhibitor-1 decreased. The changes were significant. [Conclusion] Low dose of urokinase can regulate the vasoactive substances originated endothelium obviously in patients with unstable angina pectoris. The major substances include endothelin-1, plasma tissue plasminogen activator and inhibitor-1. From this mechanism, urokinase can treat coronary heart disease effectively.
展开▼
